Menu Search
Equities

Quantum Biopharma Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0K91:MUN

Quantum Biopharma Ltd

Actions
  • Price (EUR)3.16
  • Today's Change0.08 / 2.60%
  • Shares traded30.00
  • 1 Year change-62.93%
  • Beta0.7936
Data delayed at least 15 minutes, as of Feb 16 2026 08:05 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-37.98m
  • Incorporated1998
  • Employees10.00
  • Location
    Quantum Biopharma Ltd55 University Ave. , Suite 1003TORONTO M5J 2H7CanadaCAN
  • Phone+1 (416) 854-8884
  • Fax+1 (416) 854-8884
  • Websitehttps://www.quantumbiopharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.